Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

[1]  L. Scott.  Enzalutamide: A Review in Castration-Resistant Prostate Cancer , 2018, Drugs.

[2]  J. Simões,et al.  Number Needed to Treat (NNT) and Cost of Preventing an Event (COPE) Comparison Between the Association of Cobimetinib and Vemurafenib Among Other Treatment Options for Metastatic Melanoma With BRAF V600 Mutation , 2017 .

[3]  M. Menon,et al.  The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. , 2017, European urology.

[4]  J. Lehmann,et al.  [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat]. , 2017, Der Urologe (Ausg. A).

[5]  J. Tward,et al.  Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis , 2017, Cureus.

[6]  D. Anderson,et al.  Kosteneffektivität von GnRH-Antagonisten bei Patienten mit Prostatakarzinom und kardiovaskulärem Risiko , 2017, Der Urologe.

[7]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[8]  S. Flanders,et al.  Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer , 2017, Journal of medical economics.

[9]  N. Agarwal,et al.  Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Fox,et al.  Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. , 2016, European journal of cancer.

[11]  H. D. de Koning,et al.  Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen‐detection in older (65+) men , 2016, International journal of cancer.

[12]  A. Villers,et al.  Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. , 2016, The Lancet. Oncology.

[13]  J. Schalken,et al.  Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer , 2015, BJU international.

[14]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[15]  P. Lefebvre,et al.  Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer. , 2015, American health & drug benefits.

[16]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[17]  Ronald C. Chen,et al.  Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[19]  W. Lowrance,et al.  Castration-resistant prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[20]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[21]  H. Scher,et al.  Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer , 2013, Cancer journal.

[22]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[23]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[24]  G. Dranitsaris,et al.  Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients , 2012, Supportive Care in Cancer.

[25]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[26]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[27]  E. Crawford,et al.  Characterising the castration‐resistant prostate cancer population: a systematic review , 2011, International journal of clinical practice.

[28]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[29]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[30]  R. Bender,et al.  Calculation of NNTs in RCTs with time-to-event outcomes: A literature review , 2009, BMC medical research methodology.

[31]  P. Schellhammer,et al.  A re‐assessment of the role of combined androgen blockade for advanced prostate cancer , 2004, BJU international.

[32]  P. Schellhammer,et al.  Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. , 1997, Urology.

[33]  P. Schellhammer,et al.  Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. , 1996, Urology.

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[35]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[36]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[37]  M. Greenwood.  A Report on the Natural Duration of Cancer. , 1926 .